ramucirumab,pembrolizumab
eli lilly,merck
['lcsm,(-blcsm)', 's1800a', 'lung', 'improve', 'ramucirumab']
#asco22 day 1: #lungcancer highlights 3/6 #s1800a phii rct pembro+ramucirumab vs soc post io progression
n=137 improved os (14.5m vs 11.6m). hr 0.61 no diff in orr, pfs published: #lcsm 
Associate Director Community Outreach- Thoracic Oncology-University of Miami @SylvesterCancer , Boricua en la Luna, Tweets are my own. (she/her)